{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T19:50:34Z","timestamp":1775159434087,"version":"3.50.1"},"reference-count":37,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2006,6,27]],"date-time":"2006-06-27T00:00:00Z","timestamp":1151366400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2006,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND.<\/jats:title><jats:p>The objective of this study was to characterize changes in hemoglobin (HGB) levels after the initiation of androgen\u2010deprivation therapy (ADT) in patients with previously untreated, metastatic prostate cancer who were enrolled in a large clinical trial.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS.<\/jats:title><jats:p>The multivariate associations between 3\u2010month change in HGB and baseline characteristics were evaluated with a linear regression model. The associations between 3\u2010month change in HGB level and time\u2010to\u2010event outcomes, including overall survival and progression\u2010free survival, were evaluated by using proportional hazards regression models.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS.<\/jats:title><jats:p>Quartiles of baseline HGB levels were \u226412.0 g\/dL, from 12.1 to 13.7 g\/dL, from 13.8 to 14.7 g\/dL, and &gt;14.7 g\/dL. Overall, 3 months after initiating ADT, the mean HGB level declined 0.54 g\/dL (standard deviation [SD], 1.68 g\/dL); however, the mean HGB level increased by 0.99 g\/dL (SD, 1.83 g\/dL) in patients who had baseline HGB levels &lt;12 g\/dL and decreased 1.04 g\/dL (SD, 1.28 g\/dL) in patients who had baseline HGB levels \u226512 g\/dL. After adjusting for potential confounders, including baseline HGB level, a decline in HGB after 3 months of ADT was associated independently with shorter survival (hazards ratio [HR], 1.10 per 1 g\/dL decline; <jats:italic>P<\/jats:italic> = .0035) and shorter progression\u2010free survival (HR, 1.08 per 1 g\/dL decline; <jats:italic>P<\/jats:italic> = .013). An unexpected finding was that the effect of baseline HGB on overall and progression\u2010free survival varied significantly by race.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS.<\/jats:title><jats:p>In a sample of men with newly diagnosed, metastatic prostate cancer, a decline in HGB level after 3 months of ADT was associated with shorter survival and progression\u2010free survival after adjusting for disease status and other baseline covariates. Although race alone was not a strong predictor of death or disease progression, the effect of the baseline HGB level on overall and progression\u2010free survival varied significantly by race. Cancer 2006. \u00a9 2006 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.22029","type":"journal-article","created":{"date-parts":[[2006,6,27]],"date-time":"2006-06-27T17:43:52Z","timestamp":1151430232000},"page":"489-496","source":"Crossref","is-referenced-by-count":33,"title":["The prognostic value of hemoglobin change after initiating androgen\u2010deprivation therapy for newly diagnosed metastatic prostate cancer"],"prefix":"10.1002","volume":"107","author":[{"given":"Tomasz M.","family":"Beer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine M.","family":"Tangen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa B.","family":"Bland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maha","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan H.","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas G.","family":"DeLoughery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. David","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,7,18]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000147771.92104.83"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410X.1997.00234.x"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-1611"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10673"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199810083391504"},{"key":"e_1_2_5_7_2","first-page":"7634","article-title":"Oxygenation gain factor: a novel parameter characterizing the association between hemoglobin level and the oxygenation status of breast cancers","volume":"63","author":"Vaupel P","year":"2003","journal-title":"Cancer Res."},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-002-1081-x"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)68352-8"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/pros.10162"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(02)01858-7"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000081126.71235.e0"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V80.7.1639.1639"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02983379"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1677\/erc.0.0100279"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410X.2003.04025.x"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(99)80034-X"},{"key":"e_1_2_5_18_2","first-page":"370","article-title":"Interleukin\u20106 promotes androgen\u2010independent growth in LNCaP human prostate cancer cells","volume":"9","author":"Lee SO","year":"2003","journal-title":"Clin Cancer Res."},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/pros.10288"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1207344"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.53.1.5"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19971001)80:7<1261::AID-CNCR10>3.0.CO;2-5"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/93.5.388"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2005.05561.x"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.054"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/pros.20052"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1025675303370"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2004.04.014"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/93.3.219"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1991.00400030063011"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-02-0713"},{"key":"e_1_2_5_32_2","first-page":"510","volume-title":"Hematology: Basic Principles and Practice","author":"Embury SH","year":"2000"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn.70.2.252"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197301042880108"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.2001.6426"},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-0604-3"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwh325"},{"key":"e_1_2_5_38_2","first-page":"197","article-title":"Dominance of high\u2010producing interleukin 6 and low\u2010producing interleukin 10 and interferon gamma alleles in glucose\u20106\u2010phosphate dehydrogenase\u2010deficient trauma patients","volume":"23","author":"Upperman JS","year":"2005","journal-title":"Shock."}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.22029","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.22029","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T12:24:06Z","timestamp":1760271846000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.22029"}},"subtitle":["A Multivariate Analysis of Southwest Oncology Group Study 8894"],"short-title":[],"issued":{"date-parts":[[2006,7,18]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,8]]}},"alternative-id":["10.1002\/cncr.22029"],"URL":"https:\/\/doi.org\/10.1002\/cncr.22029","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,7,18]]}}}